| Dose_mg_per_kg | Vz_L_per_kg | ke_per_h | C0_mg_per_L (derived) |
| 1.25 | 30.1 | 0.13 | 0.041528239 |
PK parameters
Summary: i.v. PK (rats) has been characterised for speciogynine; following oral kratom products (tea or a commercial shot), plasma speciogynine is typically short-lived (~1 h quantifiable) and comparatively low exposure vs other alkaloids. Metabolite profiling in rats and humans confirms phase I/II biotransformation with species differences in the number of detectable metabolites.
Key points:
Oral PK (rats): low systemic exposure; time-course short relative to mitragynine.
Metabolites: multiple phase I/II metabolites identified in rat urine; fewer in human urine after kratom use (analytical separation needed to distinguish SG from its epimer mitragynine).
